Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EPS (Weighted Average and Diluted) (2021 - 2025)

CorMedix's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.07 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 72.0% year-over-year to $0.07; the TTM value through Dec 2025 reached $2.04, up 780.0%, while the annual FY2025 figure was $2.04, 780.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.07 at CorMedix, down from $1.39 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.39 in Q3 2025 and bottomed at -$0.26 in Q2 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.01 (2024), against an average of $0.06.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 238.07% in 2023 before it surged 2880.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.26 in 2021, then grew by 20.53% to -$0.2 in 2022, then increased by 16.65% to -$0.17 in 2023, then skyrocketed by 247.06% to $0.25 in 2024, then plummeted by 72.0% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EPS (Weighted Average and Diluted) are $0.07 (Q4 2025), $1.39 (Q3 2025), and $0.28 (Q2 2025).